Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hyperthyroidism I: Introduction

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Graves Disease II: Pathophysiology

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...

Hypothyroidism II: Pathophysiology

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Historicizing health professions education research: history as a strategic analytic resource.

Advances in health sciences education : theory and practice·2026

Same author

A psychometric assessment of the Patient Health Questionnaire-9 for people living with acutely-treated HIV in Thailand.

Psychiatry research communications·2026

Same author

Long-Term Neurologic Exam Findings in People Diagnosed and Treated During Acute HIV Infection.

Annals of clinical and translational neurology·2026

Same author

Cognitive and sensorimotor impairments in virally suppressed people with and without HIV in Uganda: Associations with neurofilament light chain as a biomarker of neuronal injury.

Journal of neurovirology·2026

Same author

Long-term trends in HIV-related stigma among older adults with and without HIV: a cohort study from Mbarara, Uganda.

The Gerontologist·2026

Same author

The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial.

Nature medicine·2026

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse

Published on: October 6, 2023

[Elevation of hepatic enzyme values in hyperthyroidism].

Esa Soppi¹, Robert Paul

¹Sairaala Eira, Helsinki.

Duodecim; Laaketieteellinen Aikakauskirja

|May 11, 2011

Summary

This summary is machine-generated.

Elevated alanine aminotransferase (ALAT) in hyperthyroidism can be a diagnostic challenge. Carbimazole treatment for Graves' disease effectively normalized ALAT levels in two patients.

Related Experiment Videos

Last Updated: Jun 2, 2026

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse

Published on: October 6, 2023

Area of Science:

Endocrinology
Hepatology

Background:

Elevated serum alanine aminotransferase (ALAT) activity can occur in hyperthyroidism, posing diagnostic and therapeutic challenges.
The relationship between hyperthyroidism-induced liver enzyme elevation and primary liver disease remains an area of inquiry.
Optimal treatment strategies for managing elevated ALAT in hyperthyroid patients are not fully established.

Observation:

Two patients with Graves' disease presented with significantly elevated ALAT levels.
These elevated ALAT levels were investigated in the context of their hyperthyroid state.

Findings:

Carbimazole, a medication used to treat Graves' disease, was administered to both patients.
Following carbimazole treatment, normalized ALAT values were observed in both individuals.

Implications:

This suggests that hyperthyroidism itself, or its metabolic consequences, can directly impact liver function.
Carbimazole may be an effective therapeutic option for managing elevated ALAT associated with hyperthyroidism.
Further research is warranted to elucidate the mechanisms linking hyperthyroidism, ALAT elevation, and the therapeutic response to carbimazole.